8-KMaterial AgreementsFinancial EventsExhibits & Filings

AMGEN INC 8-K Report, Material Agreement (May 30, 2007)

Filed May 30, 2007For Securities:AMGN

Summary

Amgen Inc. (AMGN) announced on May 29, 2007, a significant financing transaction involving the issuance of $4.8 billion in aggregate principal amount of senior notes. This includes $2.0 billion in Senior Floating Rate Notes, $1.1 billion in 5.85% Senior Notes due 2017, and $900.0 million in 6.375% Senior Notes due 2037. The net proceeds from this debt offering were approximately $3.98 billion, which were raised through a private placement to qualified institutional buyers under Rule 144A and offshore investors under Regulation S, with no registration under the Securities Act of 1933. In addition to the debt issuance, Amgen also entered into an accelerated share repurchase agreement to buy back approximately 53.3 million shares of its common stock at an initial price of $59.96 per share. The company is using a significant portion of its capital for debt financing and substantial share repurchases, indicating a strategic move to manage its capital structure and return value to shareholders. The specifics of the notes, including interest rates, maturity dates, and covenants, are detailed in the filing.

Key Highlights

  • 1Amgen issued $4.8 billion in aggregate principal amount of senior notes across three tranches: Senior Floating Rate Notes ($2.0 billion), 5.85% Senior Notes due 2017 ($1.1 billion), and 6.375% Senior Notes due 2037 ($900.0 million).
  • 2Net proceeds from the debt offering were approximately $3.98 billion.
  • 3The notes were issued through a private placement, not registered under the Securities Act of 1933, targeting qualified institutional buyers and offshore investors.
  • 4Amgen entered into an accelerated share repurchase program to buy back approximately 53.3 million shares of common stock.
  • 5The initial price for the share repurchase was $59.96 per share, with potential price adjustments expected by July 31, 2007.
  • 6The debt issuance and share repurchase indicate a significant capital management strategy by Amgen.
  • 7The notes rank equally with other senior unsecured indebtedness of Amgen.

Frequently Asked Questions

The filing does not explicitly state the purpose of the debt issuance. However, given the concurrent accelerated share repurchase program, investors might infer that the company is using this capital to manage its balance sheet, potentially to fund share buybacks, make acquisitions, or for general corporate purposes.

Amgen is issuing $2.0 billion in Senior Floating Rate Notes maturing November 28, 2008, with interest at three-month LIBOR plus 0.08% payable quarterly. They are also issuing $1.1 billion in 5.85% Senior Notes due June 1, 2017, and $900.0 million in 6.375% Senior Notes due June 1, 2037, both with interest payable semi-annually.

The notes were offered and sold to initial purchasers in reliance on Section 4(2) of the Securities Act, which exempts private offerings. The initial purchasers then sold the notes to qualified institutional buyers under Rule 144A and to offshore investors under Regulation S, which are exemptions from registration requirements.

The accelerated share repurchase program indicates Amgen's commitment to returning capital to shareholders. By repurchasing approximately 53.3 million shares, the company is reducing its outstanding share count, which can potentially increase earnings per share and shareholder value.